<DOC>
	<DOCNO>NCT00634881</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . PURPOSE : This phase I/II trial study side effect best dose alemtuzumab treat patient B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Alemtuzumab Treating Patients With B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To determine safe dose alemtuzumab consolidation therapy patient second remission fludarabine phosphate alone ; fludarabine phosphate cyclophosphamide ; fludarabine phosphate , cyclophosphamide , rituximab ; bendamustine hydrochloride alone ; bendamustine hydrochloride rituximab . - To determine frequency cytomegalovirus reactivations infection alemtuzumab treatment . - To determine dose alemtuzumab efficient eliminate minimal residual disease peripheral blood bone marrow ( i.e. , turn clinical partial remission clinical complete remission [ CR ] , turn flow cytometry-positive CR flow cytometry-negative CR , turn PCR-positive CR PCR-negative CR ) . - To determine pharmacokinetic profile alemtuzumab . - To compare pharmacokinetic profile intravenous versus subcutaneous administration alemtuzumab . OUTLINE : This multicenter , dose-escalation study alemtuzumab . - Group 1 : Patients receive escalate dos alemtuzumab IV 2 hour weekly 8 week maximum tolerate dose ( MTD ) determine . - Group 2 : Patients receive escalate dos alemtuzumab subcutaneously weekly 8 week , begin MTD determine group 1 second MTD determine . Patients undergo bone marrow blood sample collection periodically laboratory pharmacokinetic study . Samples analyze minimal residual disease T-cell subset ( i.e. , CD4 CD8 ) via quantitative-PCR analysis flow cytometry cytomegalovirus antigens via PCR . After completion study treatment , patient follow 3 , 6 , 9 , 12 , 18 , 24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis Bcell chronic lymphocytic leukemia ( BCLL ) Disease complete partial remission completion 46 course secondline cytoreductive therapy le 90 day 150 day ago Secondline cytoreductive therapy must comprise 1 follow regimen : Fludarabine phosphate alone ( F ) Fludarabine phosphate cyclophosphamide ( FC ) Fludarabine phosphate , cyclophosphamide , rituximab ( FCR ) Bendamustine hydrochloride alone ( B ) Bendamustine hydrochloride rituximab chemotherapy ( BR ) Complete minimal residual disease response define follow : At least negativity 4colorcytometry and/or even PCRamplifiable clonal CDR III rearrangement IgV_H For PCR analysis , blood sample need take begin secondline cytoreductive therapy achievement clinical complete remission Disease refractory firstline F/FC/FCR/B/BR receive therapy Exclusion criterion : Presence bulky lymph node ( &gt; 5 cm ) secondline F/FC/FCR/B/BR Clinically apparent autoimmune cytopenia ( i.e. , autoimmune hemolytic anemia , autoimmune thrombocytopenia , pure red cell aplasia ) CNS involvement BCLL PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 ANC ≥ 1,500/µL Platelets ≥ 50,000/µL Creatinine ≤ 1.5 time upper normal limit ( ULN ) Conjugated bilirubin ≤ 2 time ULN Thyroid function normal Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Severe infection secondline treatment F/FC/FCR/B/BR , meet 1 follow criterion : Any episode NCI grade 4 infection More 1 episode NCI grade 3 infection Medical condition require longterm use oral corticosteroid 1 month Active bacterial , viral , fungal infection HIV , hepatitis B virus , and/or hepatitis C viruspositive serum status Concurrent severe disease exclude administration protocol therapy , include follow : NYHA class IIIIV heart insufficiency Severe chronic obstructive lung disease hypoxemia Severe ischemic cardiac disease Active secondary malignancy BCLL prior study Known hypersensitivity anaphylactic reaction murine proteins one drug component PRIOR CONCURRENT THERAPY : See Disease Characteristics No 2 prior chemotherapy , include F/FC/FCR/B/BR therapy No 1 pretreatment ( secondline therapy ) chlorambucil F/FC/FCR/B/BR No chemotherapy radiotherapy neoplastic disease BCLL prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
</DOC>